Select Medical Holdings Corporation (SEM)

Select Medical Holdings Corporation was a healthcare provider headquartered in Mechanicsburg, Pennsylvania. The business was founded in 1996 by Rocco A. Ortenzio and Robert A. Ortenzio, who built a company focused on specialty hospitals and rehabilitation services. Over time it became one of the largest operators of long-term acute care hospitals and inpatient rehabilitation facilities in the United States.

Select Medical operated through several lines of business. Critical illness recovery hospitals treated patients with serious conditions needing extended hospital care, such as respiratory failure and complex post-surgical recovery. Rehabilitation hospitals, often run in partnership with leading health systems, treated patients recovering from strokes, brain and spinal cord injuries and orthopedic conditions. A large outpatient rehabilitation network offered physical, occupational and speech therapy through clinics across many states.

The company's history included more than one period as a public company. It first went public in 2001, was acquired in 2005 by a group led by Welsh, Carson, Anderson & Stowe and Thoma Cressey, and returned to the New York Stock Exchange in 2009 under the symbol SEM. In 2010, it acquired Concentra, a provider of occupational health services, together with an investor group that included Welsh Carson.

Concentra later separated from Select Medical. It held its own initial public offering in 2024, and Select Medical subsequently distributed its remaining Concentra shares to its stockholders. After the separation, Select Medical's operations consisted principally of its critical illness recovery, rehabilitation hospital and outpatient rehabilitation businesses.

In late 2025, a consortium agreed to acquire the company. The group was led by Robert A. Ortenzio and Martin F. Jackson, both executives of the company, together with the private equity firm Welsh, Carson, Anderson & Stowe, which had a long history of investing in Select Medical. The agreement provided for $16.50 in cash per share.

The price was an 18 percent premium to the unaffected share price on November 24, 2025, and a 25 percent premium to the 90-day volume-weighted average price before that date. The purchase of outstanding shares was valued at about $1.7 billion, and the buyers financed it with equity from the consortium and a new $1 billion incremental term loan under the company's credit agreement.

The transaction was completed on or about July 1, 2026, when the company's shares ceased trading on the NYSE. A Form 25 was filed with the SEC, and the company planned to deregister its securities. Select Medical continued as a privately held company under its existing management team.